Cargando…

Anti-Vascular Endothelial Growth Factor Treatment for Proliferative Macular Telangiectasia Type 2

Idiopathic macular telangiectasia type 2 (IMT 2), is the most common type of a heterogeneous group of disorders, characterized by telangiectatic alterations of the juxtafoveolar capillary network. Vision loss is due to retinal atrophy and subretinal neovascularization (SRN). Here, we report the outc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alkin, Zeynep, Yilmaz, Ihsan, Ozkaya, Abdullah, Yazici, Ahmet Taylan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845624/ https://www.ncbi.nlm.nih.gov/pubmed/27162458 http://dx.doi.org/10.4103/0974-9233.171773

Ejemplares similares

Long Term Result of Intravitreal Bevacizumab in a Patient Newly Transformed to Proliferative Macular Telangiectasia Type 2
por: Ozkaya, Abdullah, et al.
Publicado: (2013)

Comparison of intravitreal ranibizumab between phakic and pseudophakic neovascular age-related macular degeneration patients: Two-year results
por: Ozkaya, Abdullah, et al.
Publicado: (2015)

Steroid-induced central serous chorioretinopathy in a patient with non-arteritic anterior ischemic optic neuropathy
por: Alkin, Zeynep, et al.
Publicado: (2015)

Intravitreal ranibizumab in the treatment of choroidal neovascularization secondary to morning glory syndrome in a child
por: Özkaya, Abdullah, et al.
Publicado: (2016)

Efficacy of Intravitreal Bevacizumab in Treatment of Proliferative Type 2 Idiopathic Juxtafoveal Telangiectasia
por: Baz, Ökkeş, et al.
Publicado: (2017)

Bevacizumab versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related Macular Degeneration in Turkish Patients
por: Ozkaya, Abdullah, et al.
Publicado: (2013)

Clinical Use of Dexamethasone Implants in Resistant Macular Edema Secondary to Branch Retinal Vascular Occlusion Compared with Intravitreal Anti-Vascular Endothelial Growth Factor
por: Eris, Erdem, et al.
Publicado: (2019)

The Role of Epiretinal Membrane on Treatment of Neovascular Age-Related Macular Degeneration with Intravitreal Bevacizumab
por: Alkin, Zeynep, et al.
Publicado: (2013)

Clinical Features of Untreated Type 2 Macular Telangiectasia and Efficacy of Anti-Vascular Endothelial Growth Factor Therapy in Macular Neovascularization
por: Çoban Karataş, Müge, et al.
Publicado: (2022)

Is Spectral-Domain Optical Coherence Tomography Essential for Flexible Treatment Regimens with Ranibizumab for Neovascular Age-Related Macular Degeneration?
por: Ozkaya, Abdullah, et al.
Publicado: (2013)

Focal Laser Photocoagulation in Non-Center Involved Diabetic Macular Edema
por: Perente, Irfan, et al.
Publicado: (2014)

Structural-vascular-functional correlation in type 2 non-proliferative macular telangiectasia
por: Venkatesh, Ramesh, et al.
Publicado: (2022)

Topical Nepafenac in Treatment of Acute Central Serous Chorioretinopathy
por: Alkin, Zeynep, et al.
Publicado: (2013)

Diurnal Choroidal Thickness Changes in Normal Eyes of Turkish People Measured by Spectral Domain Optical Coherence Tomography
por: Osmanbasoglu, Ozen Ayrancı, et al.
Publicado: (2013)

Comparison between Intravitreal Triamcinolone with Grid Laser Photocoagulation versus Bevacizumab with Grid Laser Photocoagulation Combinations for Branch Retinal Vein Occlusion
por: Ozkaya, Abdullah, et al.
Publicado: (2013)

Efficacy of Selective Laser Trabeculoplasty in Medically Uncontrolled Glaucoma
por: Sayin, Nihat, et al.
Publicado: (2013)

Selective Laser Trabeculoplasty for Glaucoma Secondary to Emulsified Silicone Oil after Pars Plana Vitrectomy: A Pilot Study
por: Alkin, Zeynep, et al.
Publicado: (2014)

Co occurrance of Macular Telangiectasia type 2 with hemorrhagic polypoidal choroidal vasculopathy and response to anti-vascular endothelial growth factor
por: Shah, Shreyas, et al.
Publicado: (2023)

Can Perifoveal Pseudocyst Area be a Prognostic Factor in Macular Hole Surgery?: A Prospective Study With Quantitative Data
por: Yuksel, Kemal, et al.
Publicado: (2014)

Choroidal vascularity index change in macular telangiectasia type 2
por: Chun, Heejeong, et al.
Publicado: (2022)

Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration: Real Life Clinical Experience
por: Ozkaya, Abdullah, et al.
Publicado: (2017)

Comparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy
por: Alkin, Zeynep, et al.
Publicado: (2014)

Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia
por: Berger, Tyler A, et al.
Publicado: (2021)

Intravitreal Bevacizumab Treatment in Type 2 Idiopathic Macular Telangiectasia
por: Aydoğan, Tuğba, et al.
Publicado: (2016)

Diabetic macular edema and proliferative diabetic retinopathy treated with anti-vascular endothelial growth factor under the reimbursement policy in Taiwan
por: Hsieh, Ming-Chieh, et al.
Publicado: (2022)

Ultra-Widefield Imaging of Peripheral Vascular Abnormalities in Idiopathic Macular Telangiectasia Type 1
por: Pollmann, André S., et al.
Publicado: (2021)

The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy
por: Zhao, Yue, et al.
Publicado: (2018)

A case of nodular posterior scleritis mimicking choroidal mass
por: Ozkaya, Abdullah, et al.
Publicado: (2015)

Management of Idiopathic Macular Telangiectasia Type 2
por: Khodabande, Alireza, et al.
Publicado: (2019)

When is macular edema not macular edema? An update on macular telangiectasia type 2
por: Wu, Lihteh
Publicado: (2015)

Optical coherence tomographic features of macular telangiectasia type 2: Korean Macular Telangiectasia Type 2 Study—Report No. 1
por: Kim, Young Ho, et al.
Publicado: (2020)

Impact of macular fluid features on outcomes of anti-vascular endothelial growth factor treatment for type 3 macular neovascularization
por: Yoon, Wontae, et al.
Publicado: (2021)

Anti-vascular endothelial growth factor treatment in diabetic macular edema
por: Kim, Moosang
Publicado: (2016)

Topographic Relationship between Telangiectasia and Cone Mosaic Disruption in Macular Telangiectasia Type 2
por: Zandi, Roya, et al.
Publicado: (2020)

Overlap between telangiectasia and photoreceptor loss increases with progression of macular telangiectasia type 2
por: Micevych, Paul S., et al.
Publicado: (2019)

Detailed Ophthalmologic Evaluation of Posterior Microphthalmos
por: Alkin, Zeynep, et al.
Publicado: (2014)

Suspected Neratinib Macular Toxicity Presenting As Macular Telangiectasia Type II
por: Enghelberg, Moises, et al.
Publicado: (2023)

Early-stage macular telangiectasia type 2 vascular abnormalities are associated with interdigitation zone disruption
por: Ong, Janice X., et al.
Publicado: (2021)

Analysis of candidate genes for macular telangiectasia type 2
por: Parmalee, Nancy L., et al.
Publicado: (2010)

Unusual Presentation of Type 1 Idiopathic Macular Telangiectasia
por: Bentaleb Machkour, Zaïnab, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bs0dvpnsfv1mseq71ceq53aghs